MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2025 International Congress

    Neuroprotection on the Horizon: Are GLP-1 Receptor Agonists the Next Breakthrough in Parkinson’s Disease?

    M. Helal, H. Aboushawareb, O. Hussein Abbas, R. Haddad, Y. Zain, A. S.A Osman, N. Hamam, A. Hassan (Zagazig, Egypt)

    Objective: This meta-analysis evaluates the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with Parkinson’s disease (PD). Background: Epidemiological studies suggest an increased…
  • 2025 International Congress

    Impact of Over-the-counter Cannabidiol Products on Cognition During the Course of Parkinson’s Disease

    A. López Lobato, D. Náfate Wences, A. Hernández Medrano, A. Cervantes Arriaga, M. Rodriguez Violante (Mexico, Mexico)

    Objective: To evaluate the association between Cannabidiol (CBD) usage and cognitive performance, measured by The Montreal Cognitive Assessment (MoCA) in people living with Parkinson's Disease…
  • 2025 International Congress

    Therapeutic Effect and Mechanism of Targeted Nano-selenium in Mouse Model of Parkinson’s Disease Induced by MPTP

    W. Bi, L. Zhu, T. Chen, Y. Cen, J. Zou, Z. Su (Guangzhou, China)

    Objective: In the present study, we developed a nanozyme (Se@PB-ACPP) incorporating selenium-loaded Prussian blue (PB) and modified it with an activatable cell-penetrating peptide (ACPP) to…
  • 2025 International Congress

    Prodromal Parkinson’s Disease in Agent Orange Exposed US Vietnam Veterans

    E. Uc, C. Weber, M. Lenz, J. Dawson (Iowa City, USA)

    Objective: 1-Comparing the risk of prodromal PD between AO exposed veterans (AOEV) and non-AO exposed veterans without PD (Controls) in a Veterans Affairs (VA) hospital…
  • 2024 International Congress

    ilex Paraguariensis (Yerba mate) modulates the AMPK pathway and downstream key metabolic mechanism that may explain its neuroprotective role.

    J. Ferrario, H. Hauche, L. Tschopp, T. Eidelman, M. Bordone (Buenos Aires, Argentina)

    Objective: To investigate the molecular pathways regulated by yerba mate [YM] extract and its main active compounds in a neuronal cell line as a cue…
  • 2024 International Congress

    Exercise-induced angiogenesis and midbrain neuroprotection in a mouse model of experimental PD

    T. Rodriguez, R. Smeyne, M. Smeyne (Philadelphia, USA)

    Objective: The goal of this study is to characterize microvascular changes in the SNpc in response to a neuroprotective bout of exercise. Background: Parkinson’s disease…
  • 2024 International Congress

    Time-Restricted Eating in Huntington’s Disease: Review of the Literature and a Proposed Clinical Trial

    R. Wells, L. Neilson, A. Mchill, A. Hiller (Portland, USA)

    Objective: Review recent literature on time-restricted eating (TRE) in Huntington’s disease (HD) and outline our protocol for an upcoming clinical trial designed to assess the…
  • 2024 International Congress

    Exploring the Neuroprotective Effects of Diurnal Light Exposure in Early-Stage Parkinson’s Disease: A Longitudinal, Multi-Sensory Intervention Study

    S. Putri, R. Fajar, E. Syafruddin (Gresik, Indonesia)

    Objective: This study aims to explore the neuroprotective effects of controlled diurnal light exposure on neurodegeneration rates in early-stage PD patients, positing that light therapy…
  • 2024 International Congress

    Selecting an Imaging Biomarker for a Multi-Arm Multi-Stage Trial of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Experience

    C. Gonzalez-Robles, S. Al-Bachari, M. Bartlett, R. Petty, S. Collins, R. Ellis-Doyle, G. Mills, P. Piccini, K. Pushparatnam, C. Siu, Z. Walker, M-L. Zeissler, C. Carroll, T. Foltynie, R. Weil, A. Schrag, C. Lambert (London, United Kingdom)

    Objective: To report on the selection of an imaging biomarker for a sub-study in a multi-arm, multi-stage (MAMS) platform trial for disease-modifying therapies (DMTs) in…
  • 2024 International Congress

    Therapeutic restoration of Faecalibacterium prausnitzii in Parkinson’s disease using targeted fructoligosaccharides: a double-blind, placebo-controlled, cross-over trial

    J. O'Sullivan, N. Jayabalan, N. Birch, D. Mondhe, A. Lehn, R. Gordon, R. Adan (Brisbane, Australia)

    Objective: In this study, we evaluated the effect of targeted fructoligosaccharide (FOS) therapy to restore the beneficial butyrate producer Faecalibacterium prausnitzii, one the most highly reduced…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley